Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 354C (ZNF354C)
- Target
- ZNF354C
- Molecular classification
- Transcription factor, C2H2-type zinc finger protein, KRAB domain-containing zinc finger protein
01
Overview
Zinc finger protein 354C (ZNF354C) is a protein-coding gene product and a member of the largest family of human transcription factors. It functions primarily as a DNA-binding transcriptional repressor, acting via a C2H2 zinc finger motif and a KRAB domain. ZNF354C localizes to both the nucleus and cytoplasm in endothelial and other tissue cells, repressing genes including those involved in angiogenic sprouting. It can also suppress osteogenic effects of RUNX2 and may be involved in osteoblastic differentiation and myogenesis. ZNF354C binds DNA with sequence specificity and interacts with epigenetic regulators such as TRIM28 and histones, establishing a role in negative regulation of gene expression. Its broader family, zinc finger proteins, are widely involved in cancers and other complex diseases, but there are no drugs or clinical biomarkers currently developed specific to ZNF354C.
- Other names
- ZNF354CKID3KRAB-zinc finger protein synten
02
Mechanism of action
Drugs targeting this molecule would likely function as transcriptional modulators or inhibitors; mechanism would involve modulation of its DNA-binding repressive activity.
03
Biological functions
Transcriptional repressionDNA bindingNegative regulation of sprouting angiogenesisSuppression of RUNX2 osteogenic effects, potential role in osteoblastic differentiationRegulation of postnatal myogenesis and satellite cell self-renewal (by similarity)
04
Disease associations
Cancer (general role of zinc finger proteins in tumorigenesis and tumor progression; ZNF354C specifically involved in gene regulation relevant to vascularization and tissue integrity)Other: Possible involvement in vascular pathologies or disorders associated with angiogenesis
05
Safety considerations
None specific to ZNF354C established.Potential concerns for therapeutic targeting of transcription factors include off-target gene regulation effects, impact on cell differentiation and proliferation, and general challenges of modulating nuclear proteins.
06
Biomarkers
None reported for ZNF354C specifically as a patient selection or efficacy biomarkerGeneral family (KRAB-ZNF, C2H2 ZNF proteins) implicated as transcriptional or tissue-specific biomarkers in oncology, but not ZNF354C directly
Beyond the preview
Go deeper on Zinc finger protein 354C (ZNF354C).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger protein 354C (ZNF354C).